Altamira Therapeutics Launches $12 Million Public Offering
Altamira Therapeutics Launches Significant Public Offering
Altamira Therapeutics Ltd., a company focused on advancing RNA delivery technologies beyond the liver, has made headlines with its recent public offering. This initiative aims to raise up to $12 million, comprising an upfront amount of $4 million, with potential additional proceeds of up to $8 million from milestone-linked warrants.
Details of the Offering
The offering includes a total of 5,555,556 common shares, along with accompanying Series A-1 and Series A-2 common warrants, with an attractive price point set at $0.72 per share. The Series A-1 common warrants will be immediately exercisable and could significantly enhance the company's funding as they are tied to pivotal performance milestones related to key projects, AM-401 and AM-411.
Warrants and Potential Proceeds
The Series A-1 warrants will expire in eighteen months or shortly after the announcement of positive biodistribution data, while the A-2 warrants will remain valid for up to five years, ensuring that Altamira has flexible options for fundraising as milestone events occur. If these warrants are fully exercised, they could add an additional $8 million to the company’s coffers.
Expected Closing and Use of Proceeds
The closing date for this offering is projected to be around September 19, pending customary closing conditions. The funding secured through this offering will mainly support working capital and general corporate purposes, ensuring that Altamira remains well-positioned to continue its innovative efforts.
Placement Agent Partnership
H.C. Wainwright & Co. has taken on the role of exclusive placement agent for this offering. Their expertise in executing such transactions is expected to aid Altamira in maximizing its fundraising efforts. This collaboration aligns with Altamira's strategy to strengthen its financial position as it advances its pipeline of RNA delivery technologies.
Company Background and Future Prospects
Altamira Therapeutics has been carving its niche in the biotech landscape with its innovative drug delivery platforms, OligoPhore™ and SemaPhore™, designed for effective RNA delivery beyond traditional methods. Currently focusing on two primary siRNA programs—AM-401, targeting KRAS driven cancer, and AM-411 for rheumatoid arthritis—Altamira is committed to moving these promising therapies through preclinical development.
Partnerships and Asset Management
In addition to its primary programs, Altamira also has a stake in Altamira Medica AG, which markets Bentrio®, an OTC nasal spray aimed at relieving allergic rhinitis symptoms. The company is actively exploring further partnerships and divesting from its legacy assets, indicating a clear strategy for growth and diversification in the biotech field.
Contact Information for Inquiries
For more details regarding the offering or company updates, interested parties can reach out to Altamira Therapeutics. The team is available through their contact email for inquiries regarding the offering and related ventures.
Frequently Asked Questions
1. What is the purpose of the public offering?
The public offering aims to raise funds for working capital and further the development of Altamira's innovative RNA delivery technologies.
2. How much does Altamira aim to raise through this offering?
Altamira is looking to raise up to $12 million through this public offering.
3. Who is acting as the placement agent for this offering?
H.C. Wainwright & Co. is the exclusive placement agent for this public offering.
4. What are the key programs Altamira is focusing on?
Altamira's key programs include AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical stages of development.
5. How can I get in touch with Altamira for more information?
Individuals can contact Altamira directly via their provided email address for any inquiries related to the offering or the company's operations.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Investors Urged to Act Before Deadline in Sage Therapeutics Case
- Verve Therapeutics Faces Class Action: Important Insights for Investors
- Investors Alert: Urgent Update on Sage Therapeutics Lawsuit
- Investigation of Potential Securities Fraud in Dyne Therapeutics
- Investigation Launched for Mineralys Therapeutics Investors
- eBay CFO Sells $1.9 Million in Stock: What to Know
- Y-mAbs Therapeutics Secures New Corporate Headquarters Location
- Investors of Allarity Therapeutics Encouraged to Act Now
- Verve Therapeutics Faces Class Action Lawsuit Concerns
- Photon Marine Secures $7 Million Grant for Green Initiatives
Recent Articles
- Investors of Allarity Therapeutics, Inc. Take Note of Class Action
- YHN Acquisition I Limited Sets Stage for $60 Million IPO
- Alico, Inc. Expands Credit Line for Future Growth Initiatives
- Intuitive Machines Chosen for NASA's Lunar Communications Efforts
- Microsoft and BlackRock Unite to Launch Major AI Investment Fund
- Duke Energy Foundation Invests $740,000 in Florida Education
- Innovative Sessions at the Upcoming Ad Astra Technology Summit
- Discover MSA Safety's Comprehensive Solutions for Firefighters
- Significant $300 Million Settlement for Opioid Claims Announced
- Electric AC Motors Market Growth Driven by AI and Automation
- New Leadership at Alaska Airlines to Oversee Hawaiian Operations
- Join the Ford Securities Fraud Class Action for Justice
- NASA Enhances Lunar Exploration with New Relay Contract
- Regions Financial's Strategic Move: Eliminating Series B Stock
- EnLink Midstream Plans Redemption of Series C Preferred Units
- Talis Biomedical Concludes Chicago Lease with Major Fee Payment
- OTT Market Expected to Expand by $630.5 Billion by 2028
- BGC Group Reaffirms Board Leadership and Executive Compensation
- Karyopharm's Stock Price Challenges and Future Prospects
- Industrial Barcode Scanner Market Expected to See Major Growth
- Rigetti Computing's Journey: Challenges and Innovations Ahead
- Allison Transmission Collaborates with LiuGong for Mining Innovations
- Third Century Bancorp's Commitment to Shareholder Dividends
- Cibus Inc. Plans Public Offering for Class A Common Stock
- Ventas Announces Dividend and Growth Strategies for Investors
- Blink Charging Initiative: Strategic Workforce Reductions Ahead
- Joby Aviation Executive's Recent Stock Sale and Company Updates
- Clearwater Analytics CFO Conducts Notable Stock Transactions
- Fracking Controversy: Energy Executives Back Kamala Harris
- Nerdy Inc. CFO's Share Sale: What Investors Should Know
- Third Rock Ventures Conducts Share Sale in Tango Therapeutics
- Peloton's CFO Elizabeth Coddington's Recent Stock Transactions
- Kairos Pharma Successfully Completes $6.2 Million IPO
- Toll Brothers Declares Quarterly Cash Dividend for Shareholders
- Weatherford International Set to Host Q3 2024 Earnings Discussion
- Allison Transmission Teams Up with LiuGong for Future Innovations
- MRC Global Prepares for Q3 2024 Earnings Call and Webcast
- Class Action Alert for Equity LifeStyle Properties Investors
- Cibus Plans Exciting Offering of Class A Common Shares Soon
- Healthy Choice Wellness Corp. Successfully Completes IPO Journey
- Lockheed Martin Chosen by NASA for Innovative Lightning Mapper
- Swvl Expands Operations with $2.6 Million Annual Contracts
- Intuitive Machines Secures NASA Contract Valued at $4.82 Billion
- Kroger and Albertsons Face Merger Challenges Amid FTC Hearing
- Snap Launches Cutting-Edge AR Glasses: Investor Insights
- Cryptocurrency Prices Surge Ahead of Federal Reserve Decision
- American Express to Host Third Quarter Earnings Call Live
- Pennsylvania's Renewed Push for Recreational Cannabis Legalization
- Publix Super Markets Charities Invests $11M to Combat Hunger
- Exciting New Housing Development Unveiled by Richmond American